A Comprehensive Diagnostic and Treatment Framework for Cervical Cancer Patients with Comorbidities

Abstract Cervical cancer remains a significant global health challenge [1], particularly in patients with comorbidities such as HIV, diabetes mellitus, obesity, and hypertension, which exacerbate systemic inflammation and complicate care [2,3]. This study evaluates the impact of comprehensive comorbidity management framework—encompassing antiretroviral therapy (ART), glycemic control, weight management, and antihypertensive interventions, -on overall survival (OS) and overall response rate (ORR) [4,5]. A retrospective analysis of 3,000 biomarker datasets (inflammatory markers, glycemic indices, and tumor markers) and 150 patient records revealed that effective comorbidity management was associated with improved OS (hazard ratio: 0.72 [95% CI, 0.62–0.82]; p < 0.01) and ORR (response rate: 50% vs. 35%, p = 0.01). Multivariate regression analysis accounted for confounders such as age, cancer stage, and socioeconomic factors. These findings underscore the importance of integrating targeted comorbidity management into cervical cancer care, offering a pathway to improve outcomes in high-risk patient populations [6].